© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Any story about ozagrel hydrochloride traces back to the broader search for safer, more effective antithrombotic agents. In the late twentieth century, folks were digging deep to come up with alternatives to aspirin and other blood thinners, trying to get better control over blood clots without pushing up the odds of a bleeding emergency. Ozagrel hydrochloride took shape in Japanese pharmaceutical circles as researchers hunted for ways to block the effects of thromboxane A2, a key chemical that narrows blood vessels and gets platelets sticking together inside arteries. As knowledge about platelet behavior grew, so did the drive to develop compounds that could target those signaling pathways, which led to the synthesis and clinical application of this molecule. Ozagrel hydrochloride made its debut as a selective and potent thromboxane A2 synthase inhibitor, and from there it earned a spot in both research labs and therapy plans for stroke and cardiovascular disease.
For those unacquainted, ozagrel hydrochloride stands out as a white crystalline powder, generally soluble in water and acid but not in nonpolar organic solvents. Its chemical backbone—N-(3-(4-(1H-imidazol-1-ylmethyl)phenyl)propylideneamino)benzeneacetate hydrochloride—gives it a specific set of properties. Anyone working with it quickly recognizes its mild, almost neutral smell, and the substance’s stable character at room temperature if kept away from bright light and moisture. It doesn’t break down or emit dangerous fumes unless the heating gets out of control, but anyone who's worked in a lab knows vigilance matters regardless of appearances.
The technical standards for ozagrel hydrochloride make a difference not just in scientific circles, but in hospitals and pharmacies. Pharmaceutical-grade batches usually demand a purity of over 98 percent, with strict controls on residual solvents, moisture content, and related impurities. Reliable labeling should include the chemical structure, molecular formula, and storage instructions—critical details for anyone further down the chain, whether mixing intravenous drips or running testing protocols. Proper batch documentation lines up with pharmacopoeia standards in places like Japan and China, reflecting regulators’ insistence on repeatable, traceable quality.
Synthesizing ozagrel hydrochloride takes real patience for stepwise organic chemistry. The typical prep methods involve linking an imidazole ring to an aromatic acid via a propyl chain, then turning that into a hydrochloride salt to boost stability and solubility in the body. Organic chemistry students will recall the condensation reactions and the selective reduction steps needed before acidification. Over the past decade, research teams have tried tweaking certain fragments of the molecule—changing up its side chains or swapping substituents on the imidazole—to raise its bioavailability or reduce any unwanted metabolic byproducts. The search for more selective, longer-acting derivatives continues, as scientists look to improve on the original formula without pushing toxicity.
Ozagrel hydrochloride goes by a handful of synonyms depending on where you encounter it. Most commonly, it appears under its common name ‘ozagrel.’ You’ll also spot it on research catalogs as ‘thromboxane A2 synthase inhibitor’ or, less frequently, by its code in early development studies. In Japan, the product has sold under names like ‘Antiplatelet OZ’ and other local trade marks depending on the manufacturer. Cross-border shipping or import documentation usually lists every recognized synonym to avoid any mix-ups.
Long days in labs underscore the importance of handling ozagrel hydrochloride with care, even when risk seems low. It doesn’t irritate the skin as quickly as some reactive compounds, but direct contact over time can trigger mild reactions or occupational asthma in sensitive workers. Dust masks, gloves, and fume hoods keep accidents to a minimum. Any experienced lab manager has a shelf life marked, since humidity or light can degrade its potency, risking unpredictable outcomes in dosing. Proper storage away from acids, bases, and oxidizers keeps unwanted side reactions at bay. Waste from ozagrel hydrochloride—or old test solutions—gets poured into clearly labelled containers, and handled according to local toxic waste protocols.
Studying stroke and heart attack means paying attention to the chemistry inside blood vessels, and ozagrel hydrochloride puts a wrench in platelet-driven clot formation. Cardiologists and neurologists in parts of Asia rely on it for treating acute ischemic stroke, where quick intervention cuts short the chain reaction that chokes off brain nourishment. Researchers point to studies showing positive impact on reducing recurrence of vascular events, and physicians value its fairly specific action compared to older, broader blood thinners. Its effects have been explored in diabetes, chronic kidney disease, and autoimmune conditions where microcirculation problems cause real headaches. Scientists also use ozagrel hydrochloride in animal models to explore the tangled links among vascular inflammation, oxidative stress, and neurotransmitter signaling—the kind of research that eventually spins off new hope for tough-to-treat disorders.
Ozagrel hydrochloride’s chemical toolkit goes well beyond established clinical applications. Basic researchers keep it close by as a probe to figure out how platelets signal to each other during inflammation, surgery, or trauma. Translational scientists dig into whether blocking thromboxane A2 can slow progression of diseases from Alzheimer’s to multiple sclerosis. Each new clinical trial brings another round of insight—or frustration. Resistance among platelets, off-target effects, or practical issues with oral versus intravenous delivery all shape the path forward. Progress hasn’t been a straight line, but fresh analytical tools and high-throughput screening methods let researchers hunt for new analogs and refine delivery strategies. These innovations signal hope for more tailored approaches down the road, especially for patients who don’t respond well to mainstream antiplatelet agents.
Experience teaches that every powerful medication brings risk. Toxicology studies on ozagrel hydrochloride underline the real possibility of bleeding complications, changes in liver enzymes, and impacts on gastrointestinal lining under high or repeated dosing. Animal studies spotlight reproductive and developmental effects at doses far above therapeutic range, reminding researchers and clinicians not to take any shortcuts. The risk profile stacks up against other antiplatelets, and debates over where to draw the line on dose and duration still occupy medical journals. Physicians must weigh the clear benefit in cutting clot risk against the shadow of unwanted side effects. Proper screening, attentive monitoring, and patient education never go out of style, even as pharmaceutical marketing pushes new favorites every few years.
Science thrives on curiosity, and the ozagrel hydrochloride story is still being written. The ongoing search for more targeted antiplatelet drugs drives pharmaceutical companies and academic teams to keep tweaking formulas, changing delivery routes, or pairing ozagrel hydrochloride with complementary therapies. Each improvement raises hopes for faster, safer, or more versatile treatments—reducing risk of stroke and cardiovascular events for patients who can’t tolerate older regimens. With more data from global real-world use and deeper understanding from molecular biology, the future could hold more precise guidelines for personalizing treatment. Researchers also keep their eyes on combinations with other anti-inflammatory agents, as the overlap between clotting and inflammation opens doors for new therapeutic strategies. Beyond the bedside, ozagrel hydrochloride’s role as a scientific tool looks secure, helping to illuminate the subtle chemical dance at work in every narrowing artery or healing wound. The next chapter, like much in medicine, depends on persistence, open-minded collaboration, and real attention to each patient’s story.
Ozagrel Hydrochloride doesn’t come up often outside of specialist conversations. In hospitals and research labs, though, it grabs attention for its action on blood clots and its potential to help people recover after a stroke. Years ago, I watched a close friend’s father grapple with life after a minor stroke. Doctors explained the risk of new clots lurking in his future. That anxiety never fully faded, so any medicine that can lower those risks matters a lot to families like his.
Human bodies rely on platelets to stop bleeding, but sometimes they go into overdrive and block blood flow where it shouldn’t be blocked, especially in the brain. Ozagrel Hydrochloride blocks an enzyme called thromboxane A2 synthase. This enzyme helps platelets clump together. Blocking thromboxane means fewer unnecessary clots. Less risk of those dangerous blockages that lead to strokes or heart attacks.
Doctors in Japan, where Ozagrel Hydrochloride gets most of its real-world use, often use it for treating acute cerebral infarction. Acute just means the problem started suddenly and needs attention fast. Most ischemic strokes come from blockages, not ruptures. That’s exactly the area where Ozagrel steps in, and time matters a lot—every hour without treatment can damage the brain further.
Strokes rank among the top killers worldwide. In the U.S., someone dies from a stroke about every four minutes. The main treatments available—like tissue plasminogen activator (tPA), which dissolves clots—work for some patients, but not all. Sometimes they can’t receive tPA because of bleeding risk or arriving too late. Doctors need more options. In countries where it’s available, Ozagrel gives physicians another way to fight back, cutting platelet clumping before it causes more harm.
Older people face bigger risks, but strokes hit younger people, too. Sudden disabilities, lost jobs, long rehabilitation—not everyone bounces back. Medicines that make future clots less likely can prevent heartache and huge costs down the line. Stroke survivors feel this firsthand.
No medicine comes with zero drawbacks. Too much blocking means a higher chance of bleeding—nosebleeds, gum bleeds, or even more severe internal bleeding. The best results often come with careful hospital monitoring and teamwork between doctors and pharmacists. Ozagrel’s not as widely studied in the United States or Europe. Part of that traces to how U.S. and European regulators set out different standards for what gets approved.
Access becomes a problem. Until large clinical trials confirm benefits and safety across more ethnic groups and in more settings, Ozagrel Hydrochloride’s full potential stays just out of reach for many patients. That research gap needs closing. The pharmaceutical industry and public health funders have a responsibility here—to back trials and publish transparent results.
Strokes shatter lives, so medicines that lower those odds carry real weight. Ozagrel Hydrochloride hasn’t made headlines outside of Japan, but its story points to wider gaps in treatment and access. Reliable answers require open data, diverse patient populations, and health professionals’ voices. Patients and families want clarity and hope. Research, education, and better access can all play a part in making sure promising medicines like Ozagrel Hydrochloride can help more people rebuild after stroke.
Ozagrel Hydrochloride treats conditions like stroke, heart attacks, and other problems where blood clots play a dangerous role. Doctors prescribe it to keep blood flowing smoothly by reducing platelet aggregation. This power isn't without risk. Just like with aspirin or clopidogrel, folks might run into trouble if things go off track.
Bleeding stands as the main concern here. Since Ozagrel Hydrochloride blocks clot formation, people might notice bruising that shows up fast or bleeding that just won't quit. Gum bleeding, nosebleeds, longer bleeding from cuts—I've seen patients get worried over what starts off looking mild. In some hospitals, we check stool for hidden blood to catch gastrointestinal bleeding early.
Doctors monitor folks closely for serious problems: stomach ulcers can bleed, and brain bleeds can happen in rare cases. I've talked to patients who brushed off headaches or odd symptoms, only to land in the emergency room because they didn't realize a tiny vessel in the brain broke—something that can be life-changing.
Beyond bleeding, some people complain of gastrointestinal upsets. Nausea, vomiting, and diarrhea show up in some reports. Drug labels from Japan—the only country where Ozagrel Hydrochloride gets wide use—mention liver problems, seen as yellow eyes or skin, or dark urine. Doctors run liver tests to catch these troubles before they go too far.
Skin rashes or itching creep in for a small number of people. Allergic reactions paint a bigger red flag. Swelling in the face, lips, or throat, or trouble breathing, signals a medical emergency.
Ignoring early signs invites disaster. A friend of mine once thought he had the flu, but his stubborn nosebleed meant Ozagrel Hydrochloride was causing more harm than good. Catching side effects early, and paying attention to how folks feel, cuts down on rare but severe consequences.
Older adults and those taking other blood thinners stand at much higher risk. Polypharmacy—mixing many prescriptions—often complicates things. Families and caregivers should watch for changes and never assume bleeding or stomach symptoms stay minor.
Doctors need to spell out the risks clearly before sending anyone home with this medicine. Conversation beats paperwork. I’ve found that when people know what to look for—unexpected bruises, colored stool, or confusion—they seek help sooner.
Hospitals and clinics must keep tabs on lab tests for liver enzymes and blood counts. Routine checkups matter. Catching a falling red blood cell count, or spotting something off in liver numbers, can stop problems before they spiral.
Education stands as a strong defense. Some Japanese hospitals issue illustrated guides showing signs of internal bleeding or skin rashes. In my experience, visual reminders stick better than dense leaflets.
Coordination between primary care, specialists, and pharmacists offers another safety net. Digital records that alert when someone’s dose climbs too high, or when medicines interact, have caught issues more than once in my corner of healthcare.
Encouraging people to report even mild symptoms—especially with meds like Ozagrel Hydrochloride—keeps folks safer. Open lines of communication make patients true partners in their care. Informed people tend to do better, because they don’t wait to say something feels off.
Ozagrel Hydrochloride lands on the treatment table for people experiencing trouble with blood clots, especially during the early stages after a stroke. I’ve noticed in my years talking with neurologists and pharmacists, drugs aimed at thinning the blood or blocking clotting often come with serious rules about how and when to take them. It isn’t just about swallowing a tablet or getting an injection; it’s about timing, supporting care from medical teams, and checking personal health factors that don’t always get listed in the textbook.
Doctors usually pick intravenous administration for Ozagrel Hydrochloride. They aren’t flipping a coin. The body absorbs this kind of medicine in a much more predictable way through an IV. That outcome matters most in critical care settings where waiting for a pill to dissolve could mean missing tight treatment windows. Once inside the bloodstream, Ozagrel Hydrochloride works hard to reduce the formation of potentially dangerous clots.
During an acute stroke, minutes count. Ozagrel Hydrochloride goes in by slow drip, allowing the body to adjust and avoiding heavy swings in concentration. Hospital teams often start with a loading dose and then shift to a steady infusion. Doses rest on trusted clinical research—often 80 mg diluted, run through IV over two hours, followed by 40 mg every twelve hours, but this gets adjusted for each patient. These numbers come from years of study. Even something like dehydration or kidney function tweaks the dose.
In the real world, not every patient behaves like the textbook says. Every doctor I’ve met insists on watching lab results closely: platelet levels, kidney markers, and signs of bleeding. Someone on blood thinners or with liver impairment demands more attention. The care team watches for bruising, blood in the urine, or confusion—early signs that a dose might need adjusting or that stopping the drug is safer.
I’ve seen doctors debate whether to keep Ozagrel Hydrochloride going if a patient develops headaches or low blood pressure. Sticking with the protocol sounds simple, but balancing the risks for each individual never is.
Some clinicians have run into trouble with allergic reactions and want allergy histories upfront. Others call for more clear communication from manufacturers about storage and dilution—since Ozagrel Hydrochloride isn’t always stable at room temperature after mixing. Nurses and pharmacists talk among themselves about safe handling, especially since breaks in the infusion or incorrect mixing can compromise results or create more risk than benefit.
Clear training and detailed guides help staff give Ozagrel Hydrochloride safely. Hospitals making protocols available on every ward, along with regular refresher sessions, cut down on mistakes. Investing in digital systems that alert doctors to potential drug interactions or warn about low platelet counts goes a long way. In clinics with limited experience, partnering with larger centers can save patients from avoidable harm.
Ozagrel Hydrochloride promises real help in managing certain strokes and clotting disorders. Proper administration doesn’t just depend on the drug itself—it hangs on teamwork, up-to-date knowledge, and a strong focus on patient safety at every turn.
No one takes medicine planning for trouble, but sometimes different drugs start causing problems together. Ozagrel Hydrochloride, used to keep blood from clotting too much, lands on a doctor’s radar for its role in preventing the stuff that leads to strokes and heart issues. Mixing it up with other medicines can lead to bleeding risks or make some drugs less effective. Doctors usually ask about everything you’re taking, and for good reason—missing a detail can cause a pile-up of side effects.
Ozagrel Hydrochloride keeps platelets from clumping, which helps folks with clotting problems. Taking it with certain other drugs isn’t like tossing extra cheese on pizza—too much of a good thing can bring trouble. Aspirin, warfarin, and other blood thinners like heparin can mix with Ozagrel, pushing bleeding risks higher. Even some anti-inflammatory painkillers, like ibuprofen, add to the problem. In a hospital, doctors track signs like sudden bruises or blood in the toilet, but at home, noticing these signs matters just as much.
You might expect most trouble with prescription drugs, but over-the-counter stuff gets overlooked too. Herbs like ginkgo biloba or fish oil also thin blood. Someone might think popping a supplement is harmless, not realizing it adds to Ozagrel’s effect. There have been real cases: a person taking both found their nose bleeds wouldn’t stop. These stories drive home why open conversations with the pharmacist and doctor can save you grief.
It gets more complicated for folks juggling high blood pressure or diabetes drugs. Ozagrel influences how blood flows, and pairing it with hypertension pills like ACE inhibitors or calcium channel blockers sometimes causes unpredictable blood pressure drops. Women and the elderly, in particular, seem to feel these shifts faster, maybe due to other illnesses weighing in. Doctors often recommend closer monitoring to spot risky changes early.
Diabetics face another curveball. Ozagrel alters prostaglandin levels, which might mess with the way the body handles insulin. The science isn’t airtight yet, but it makes sense to talk to your care team before starting Ozagrel, especially if you already use insulin or medicines like metformin. Keeping track of blood sugar can help catch surprises before they turn into bigger issues.
People have more control over medicine safety than they probably think. Take a current list of everything you use, including supplements, to each appointment. Don’t leave out anything, even if it seems minor. Ask if new drugs will clash with what you already take. Watch out for bleeding, easy bruising, or funky blood pressure numbers at home. Small things—reporting nosebleeds or feeling dizzy—can help doctors tweak your treatment before problems snowball.
Pharmacists, not just doctors, are trained to spot risks. Call the pharmacy before grabbing new over-the-counter meds or supplements. Electronic health records and pharmacist reviews help flag red flags, but nothing replaces honest back-and-forth communication between everyone on the care team—including the patient.
Making sure Ozagrel Hydrochloride helps, not harms, takes more than just a prescription. Science shows people fare best when medical teams talk openly about the meds they’re using, keep an eye out for bleeding signs, and adjust plans as needed. Education, speaking up, and building a habit of checking before mixing drugs really do pay off, both in fewer surprises and better health overall.
Ozagrel Hydrochloride shows up in hospitals for patients who need protection against clots, especially after strokes or heart attacks. The drug works by thinning blood, blocking substances that make clots form. This can save lives, but not everyone can handle what this kind of drug does.
Patients who bleed easily, or have medical histories of stomach ulcers or brain bleeds, deal with high risk if doctors offer this medicine. I’ve watched loved ones struggle after surgeries where blood-thinners did more harm than good. Ozagrel Hydrochloride can make existing bleeding much worse—nosebleeds, gum bleeding, or bruises aren’t just mild side effects here. The risk ramps up for anyone with hemophilia or other clotting factor issues. The medicine’s intended benefit flips, leading to serious danger.
Those living with severe liver or kidney disease don’t clear drugs from their bodies the way healthy people do. Ozagrel could pile up inside, causing unpredictable reactions. That’s not a theory—hospital charts show cases where drug levels got too high simply because the kidneys stopped working as hard. These patients should look for other treatment options.
Expectant mothers and women nursing newborns face tough decisions. Every medicine reaches babies across the placenta and into breast milk. For Ozagrel Hydrochloride, research doesn’t give clear answers about harm to unborn or breastfeeding infants. In my own family, we found doctors chose older, proven-safe drugs during pregnancy, and skipped new medicines unless there was no choice—safety for the baby comes first every time.
People who have reacted badly to similar drugs in the past run a clear risk. Rashes, swelling, difficulty breathing, and other signs of allergy can come quickly. I’ve seen people experience anaphylaxis right after trying something new. It isn’t worth the gamble. Safety requires knowing what a patient reacted to in the past—including not just Ozagrel Hydrochloride itself, but ingredients inside the tablets.
Ozagrel Hydrochloride doesn’t work in isolation. Many people fighting heart disease, high blood pressure, or diabetes already take blood thinners or blood pressure pills. Combining these can multiply risks. For example, combining with aspirin, warfarin, or even herbal products like ginkgo can lead to severe bleeding. Doctors try to spot these problems, yet honest conversations between patients and doctors make the biggest difference. From what I’ve seen, people speaking up about every supplement and medicine they use avoid the most trouble. It’s not only about prescription drugs—over-the-counter pain relievers or vitamins could also mix badly.
Ozagrel Hydrochloride helps many, but some groups face bigger harm. Reading up on medicines isn’t enough. People living with bleeding disorders, organ failure, pregnancy, known drug allergies, or already juggling several prescriptions should think twice. A trusting relationship with doctors and pharmacists makes all the difference—patients who ask direct questions often get safer, more tailored care. No one should feel rushed into taking a strong medicine if real risks are present.
| Names | |
| Preferred IUPAC name | sodium (E)-3-(4-(2-oxoazetidin-1-yl)phenyl)-2-propenoate hydrochloride |
| Other names |
OKY-046 Ozagrel HCl |
| Pronunciation | /ˈoʊzəˌɡrɛl haɪˌdrɒklaɪd/ |
| Identifiers | |
| CAS Number | [87336-95-4] |
| Beilstein Reference | 3647167 |
| ChEBI | CHEBI:76358 |
| ChEMBL | CHEMBL2104391 |
| ChemSpider | 16735854 |
| DrugBank | DB12460 |
| ECHA InfoCard | 100.137.434 |
| EC Number | EC 607-736-9 |
| Gmelin Reference | 1295646 |
| KEGG | D08303 |
| MeSH | Ozagrel Hydrochloride"[MeSH] |
| PubChem CID | 65645 |
| RTECS number | SN5622850 |
| UNII | 25TI1X7W5E |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C20H19ClN2O4 |
| Molar mass | 437.89 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 0.8 |
| Acidity (pKa) | 13.57 |
| Basicity (pKb) | 4.35 |
| Magnetic susceptibility (χ) | -64.9e-6 cm³/mol |
| Refractive index (nD) | 1.645 |
| Dipole moment | 2.36 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 321.2 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | B01AC10 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | `GHS07` |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | Store in tight container at room temperature. |
| Flash point | > 267.3 °C |
| Lethal dose or concentration | LD50 (rat, oral): > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous LD50 = 262 mg/kg |
| NIOSH | DN0 |
| PEL (Permissible) | Not Established |
| REL (Recommended) | 300 mg daily |
| Related compounds | |
| Related compounds |
Ozagrel Epoprostenol Iloprost Beraprost Picotamide Triflusal |
